Credit Suisse Ag Adverum Biotechnologies, Inc. Transaction History

Credit Suisse Ag

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $14,853 - $23,548	-12,076 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $103,342 - $142,540	-59,392 Reduced 83.1%	12,076 $21,000
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $5,424 - $9,388	2,608 Added 3.79%	71,468 $154,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $1,360 - $4,276	405 Added 0.59%	68,860 $241,000
Q1 2021 May 14, 2021	SELL	$9.26 - $14.36 $222,582 - $345,171	-24,037 Reduced 25.99%	68,455 $675,000
Q4 2020 Feb 12, 2021	SELL	$9.84 - $14.26 $688,268 - $997,429	-69,946 Reduced 43.06%	92,492 $1 Million
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $652,278 - $1.37 Million	63,328 Added 63.9%	162,438 $1.67 Million
Q2 2020 Aug 12, 2020	BUY	$8.53 - $25.64 $409,363 - $1.23 Million	47,991 Added 93.88%	99,110 $2.07 Million
Q1 2020 May 13, 2020	SELL	$7.98 - $16.32 $325,807 - $666,312	-40,828 Reduced 44.4%	51,119 $500,000
Q4 2019 Feb 12, 2020	BUY	$5.12 - $12.22 $408,320 - $974,545	79,750 Added 653.85%	91,947 $1.06 Million
Q3 2019 Nov 12, 2019	BUY	$5.24 - $15.89 $985 - $2,987	188 Added 1.57%	12,197 $66,000
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $2,289 - $5,338	-449 Reduced 3.6%	12,009 $143,000
Q1 2019 May 14, 2019	SELL	$3.03 - $6.02 $1,563 - $3,106	-516 Reduced 3.98%	12,458 $65,000
Q4 2018 Feb 13, 2019	BUY	$2.87 - $5.92 $37,235 - $76,806	12,974 New	12,974 $41,000
Q3 2018 Nov 13, 2018	SELL	$4.5 - $7.6 $70,056 - $118,316	-15,568 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$5.3 - $6.9 $82,510 - $107,419	15,568 New	15,568 $82,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.